PG
NBIX icon

PEAK6 Group’s Neurocrine Biosciences NBIX Stock Holding History

PEAK6 Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$1.34M Sell
13,649
-11,535
-46% -$1.03M 0.01% 1712
2018
Q1 		$2.09M Buy
+25,184
New +$2.13M 0.01% 1335

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

PEAK6 Group's NBIX Position: Q2 2018 in Review

PEAK6 Group reduced its Neurocrine Biosciences (NBIX) stake by 46% in Q2 2018, selling an estimated $1.03M and leaving 13,649 shares worth $1.34M. The position accounts for 0.01% of the portfolio, ranked #1712.

PEAK6 Group first reported a position in NBIX in Q1 2018 and has held it in 2 quarters since. The position peaked at $2.09M in Q1 2018. 274 funds tracked by Wall St. Rank hold NBIX as of Q2 2018.

  • PEAK6 Group held 13,649 shares of Neurocrine Biosciences worth $1.34M as of Q2 2018.
  • PEAK6 Group sold 11,535 Neurocrine Biosciences shares in Q2 2018, an estimated $1.03M.
  • Neurocrine Biosciences made up 0.01% of PEAK6 Group's portfolio in Q2 2018, its #1712 holding.
  • PEAK6 Group first reported a position in Neurocrine Biosciences in Q1 2018 and has held it in 2 quarters since.
  • PEAK6 Group's Neurocrine Biosciences position peaked at $2.09M in Q1 2018.
  • 274 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.